EMA begins analysis of Pfizer-BioNTech’s Covid-19 booster shot data

The European Medicines Agency (EMA) has commenced evaluation of an application submitted by Pfizer and BioNTech seeking an update to conditional marketing authorization (CMA) for the use of a booster shot of their Covid-19 vaccine, Comirnaty. A messenger ribonucleic acid (mRNA) vaccine, Comirnaty was granted a CMA by the European Commission in December last year. The third or booster shot is intended to be administered six months after the second dose in individuals aged 16 years or above, Pfizer noted.